Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
Laura-Maria Madanat-HarjuojaLindsay A RenfroKelly S KlegaBrett TornwallAaron R ThornerAnwesha NagDavid DixJeffrey S DomeLisa R DillerConrad V FernandezElizabeth A MullenBrian D CromptonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
ctDNA demonstrates promise as an easily accessible prognostic biomarker with potential to detect tumor heterogeneity. The observed trend toward more favorable outcome in patients with undetectable ctDNA requires validation. ctDNA profiling should be further explored as a noninvasive diagnostic and prognostic tool in the risk-adapted treatment of patients with WT.
Keyphrases
- circulating tumor
- circulating tumor cells
- cell free
- single cell
- palliative care
- young adults
- clinical trial
- study protocol
- randomized controlled trial
- phase iii
- big data
- machine learning
- risk assessment
- combination therapy
- climate change
- open label
- deep learning
- human health
- replacement therapy
- smoking cessation
- double blind